Navigation Links
Mylan Reiterates and Stands Behind Its 48-Year Commitment and Track Record of Quality
Date:7/26/2009

PITTSBURGH, July 26 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) released the following response to a news article published earlier today:

"An article published today about an issue related to a Standard Operating Procedure (SOP) was based on improperly obtained documents, uninformed third-party commentary and anonymous sources. Simply put, our investigation of the issue demonstrates that our quality systems are working, not the contrary. Our customers and stakeholders can rest assured that whenever there is even the slightest departure from an SOP, it will be dealt with immediately and effectively. This issue had no impact on the quality of our product."

Mylan Inc., which provides products to customers in more than 140 countries and territories, ranks among the leading diversified generic and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest - and highest quality - product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's third largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies. For more information, please visit www.mylan.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Mylan Receives FDA Approval for Additional Strengths of the Antipsychotic Haloperidol
2. Mylan Declares Quarterly Preferred Stock Dividend
3. Mylan Receives FDA Approval for Generic Version of Thyroid Deficiency Treatment Cytomel(R)
4. Mylan Schedules Second Quarter 2009 Financial Results Conference Call and Live Webcast
5. Mylan Receives FDA Approval for Additional Strength of Generic Restoril(R)
6. Mylans Chief Operating Officer Heather Bresch to Testify Before Congress Concerning Patent Settlements Between Brand and Generic Pharmaceutical Companies and Tactics That Delay Market Entry of High Quality, Affordable Generic Drugs
7. Mylan Announces Successful Matrix Delisting Offer
8. Mylan Announces Change in Board Leadership
9. Mylan Receives Final FDA Approvals for Generic Versions of Anti-Rejection Medication CellCept(R)
10. Mylan Schedules First Quarter 2009 Financial Results Conference Call and Live Webcast
11. Mylan Declares Quarterly Preferred Stock Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 28, 2017 , ... ... of two biometric time and attendance tracking products: the new NCheck Cloud Bio ... Cloud Bio Attendance uses biometric face recognition to enable users to check in ...
(Date:3/28/2017)... Appleton, WI (PRWEB) , ... March 28, 2017 ... ... how self-funded health plans work, the Self-Funding Success website has recently developed and ... about Self-Funded Health Plans ” was created based on common inquiries the site’s ...
(Date:3/28/2017)... ... , ... A minimally invasive porcelain veneer is increasing in ... of Dental Laboratories (NADL) is informing dentists about the benefits of minimally invasive ... laboratories and technicians that create these veneers. , According to National Board ...
(Date:3/28/2017)... Kennett Square, PA (PRWEB) , ... March 28, 2017 , ... ... reputation online and across a variety of business channels. , While many results ... aspects of any public relations program. , When it comes to measurement, firms ...
(Date:3/28/2017)... ... 2017 , ... Silicon Valley Hair Institute, the San Francisco Bay Area leader ... women’s hair loss. Although hair transplant procedures can be seen as more of a ... can be two reasons a woman may see her hair thinning. , “We are ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... 27, 2017   Pulmatrix, Inc . (NASDAQ: PULM), a ... serious pulmonary diseases, today announced that it has added two ... and asthma to its Scientific Advisory Board . ... Richard B. Moss , MD, former chief of the Pediatric ... Fibrosis Center at Stanford University, and ...
(Date:3/27/2017)... , March 27, 2017 ... to reach USD 16.0 billion by 2025, according to ... growing prevalence of chronic diseases is anticipated to be ... analyzers, which thereby widens the scope for growth during ... and bariatric population, which is highly susceptible to chronic ...
(Date:3/27/2017)... BOSTON , March 27, 2017  Allergan ... and Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a biopharmaceutical ... innovative therapies based upon tetracycline chemistry, announced that ... the treatment of moderate to severe acne met ... a once-daily, oral, narrow spectrum tetracycline-derived antibiotic with ...
Breaking Medicine Technology: